Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domestic bortezomib + lenalidomide + dexamethasone induction study in newly diagnosed multiple myeloma
ChiCTR2000040808Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Shandong Cancer Hospital. Primary endpoint: very good partial response rate. Started Jan 2020; status: recruiting.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000040808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040808.